Literature DB >> 9508650

[Indications for percutaneous atrioseptostomy. Comparison of echocardiographic and fluoroscopic monitoring].

S Guarnera1, M Contarini, P Sciacca, L Patanè, M G Parisi, A Pulvirenti, M Marletta, G D'Agata, G Distefano.   

Abstract

Balloon atrial septostomy (BAS) is of established value in the management of several congenital heart diseases in the neonatal period. This procedure, which leads to creation of a tear in the membrane of the Foramen Ovalis using a balloon catheter, may be undertaken under fluoroscopic monitoring in catheter laboratory as well as under echographic control, even bedside. In this study we present our experience and discuss the indications to these two techniques. 91 neonates underwent to BAS; in 14 of them this was carried out under two-dimensional echocardiographic control in the intensive care unit. In all the patients BAS had good result, with clinical improvement in the majority of cases (97%) and a low rate (6%) of minor complications (such as transient supraventricular arrhythmias), without differences between fluoroscopic and ultrasound monitoring. The higher rate of mortality in the fluoroscopic monitoring group (2/91 = 2.2%) was thought to depend on an extremely critical presentation of the neonates. The echographic monitoring does not seem to offer any real advantage from the technical point of view, but the necessity of a prompt treatment of very ill patients emphasizes the advantages of a quickly and easily feasible procedure. Thus, we recommend the use two-dimensional echocardiographic imaging only in the very ill neonates in whom the septostomy can be more safely performed in intensive care unit bedside.

Entities:  

Mesh:

Year:  1997        PMID: 9508650

Source DB:  PubMed          Journal:  Pediatr Med Chir        ISSN: 0391-5387


  1 in total

1.  Balloon atrial septostomy through internal jugular vein in a 45-day-old child with transposition of great arteries.

Authors:  Sumanta S Padhi; Kinjal D Bakshi; Avinash P Londhe
Journal:  Ann Pediatr Cardiol       Date:  2010-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.